Dicerna Pharmaceuticals (DRNA) PT Lowered to $25 at Citi
Tweet
Share
E-mailGet Alerts DRNA Hot Sheet
Price: $38.22 --0%
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 4 | New: 7
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 4 | New: 7
Join SI Premium – FREE
Citi analyst Yigal Nochomovitz lowered the price target on Dicerna Pharmaceuticals (NASDAQ: DRNA) to $25.00 (from $30.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Berenberg Upgrades Accelleron Industries AG (ACLN:SW) to Buy
- Schott Pharma AG (1SXP:GR) PT Raised to EUR27 at Berenberg
- Keefe, Bruyette & Woods Downgrades Crescent BDC (CCAP) to Market Perform
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
